{"podcast":{"title":"Oncology Today with Dr Neil Love","slug":"oncology-today-with-dr-neil-love-1004241","podcast_index_feed_id":1004241,"rss_url":"https://feeds.captivate.fm/oncologytoday/","website_url":"https://www.researchtopractice.com","image_url":"https://artwork.captivate.fm/464a03b3-1b7f-4b39-a2c6-e3de4b1e77b7/8YAjpM6wBeZeb3Gyb3zbR3bE.jpg","author":"Dr. Neil Love","episode_count":463,"summary":"Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.","last_synced_at":"2026-07-28T06:21:37.419138+00:00","page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241"},"episode":{"title":"Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway","slug":"breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway","published_at":"2026-07-25T13:00:00+00:00","page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway","show_page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241","url":"https://oncologytoday.captivate.fm/episode/6082-asco2026-serds-pi3k-akt-mtor-bc","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/240a27db-2e18-410b-af36-0f9357d5f6aa.mp3","summary":"Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications","meta_description":"Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney,…","key_points":[],"chapters":[],"topics":[],"duration_seconds":7096,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}